Field Medical Publishes 12-Month Outcomes from Field PULSE Trial

Late-breaking HRX data have advanced Field Medical's "instantaneous ablation" workflow and expanded the clinical evidence for high-voltage focal pulsed field ablation (PFA) with the FieldForce™ PFA System. The company today announced the publication of 12-month results from the first-in-human Field PULSE trial in JACC: Clinical Electrophysiology. The findings were presented simultaneously as a Late-Breaking Clinical Trial at HRX Live 2026.

Field Medical developed the FieldForce™ PFA System around a high-voltage focal PFA architecture designed for the ventricle, where depth, stability, and control are among the most challenging aspects of ablation. Field PULSE extends this work into the atrium and evaluates a subsecond point-by-point workflow Field Medical terms "instantaneous ablation." In this study, the approach was associated with procedural efficiency, durable pulmonary vein isolation (PVI), and flexibility beyond the pulmonary veins, without the need for prolonged catheter stability.

Key findings from the study include: - Procedural efficiency with subsecond focal PFA: 13-minute median elapsed PVI ablation time, with a fastest time of 7.7 minutes. - Durable PVI with the optimized waveform: 94.2% per-vein durability, reflecting progressive improvement with waveform evolution. - Flexible focal ablation: 49% of patients received non-PV ablation for additional atrial targets. - No primary safety events were observed. - 80% freedom from atrial arrhythmias at 12 months with the optimized waveform.

"Delivering the full application in less than 200 milliseconds reduces the need for prolonged catheter stability while preserving the flexibility of point-by-point ablation. The procedural efficiency, safety, and pulmonary vein durability observed with the optimized waveform support continued clinical development of this approach."

The publication builds on Field Medical's peer-reviewed clinical work in ventricular tachycardia. Six-month outcomes from the company's first-in-human VCAS trial were published in Circulation in 2025. Field PULSE now adds first-in-human, peer-reviewed atrial data evaluating the same high-voltage focal PFA architecture through a distinct focal workflow in a different cardiac substrate.

"Field PULSE demonstrates that the same high-voltage focal PFA architecture can support an 'instantaneous ablation' workflow in the atrium. This growing body of evidence reinforces the range of the platform: depth and focal control in the ventricle, speed and precision in the atrium, and the versatility to address very different cardiac substrates through a familiar point-by-point approach. These results add important clinical evidence as we continue to advance our differentiated PFA platform."

DOI: 10.1016/j.jacep.2026.09.001.